Therefore, while the insulin replacement study suggests that dapagliflozin exerts the majority of its effect through reversing hyperinsulinemia, future studies would be required to rule out potential effects of dapagliflozin on each of these other mediators of tumor growth. The gene discussed is INS; the disease is Hyperinsulinemia.